Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMETHYST study of litifilimab in active cutaneous lupus erythematosus
2023-505634-94-00Phase 3Authorised
- Sponsor
- Biogen
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in subacute cutaneous lupus erythematosus (SCLE) and discoid lupus erythematosus (DLE) comparing Litifilimab with Placebo (2 arms). Planned start Feb 2023; status: authorised.
02
Drugs
litifilimab
03
Conditions
subacute cutaneous lupus erythematosus (SCLE)discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on 2023-505634-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505634-94-00.